Yesterday we looked at ten innovative approaches centred around T cell-based developments emerging from the American Society of Hematology (ASH) meeting that is taking place in Orlando next month.

Let’s not forget, however, that there are also other immune cells, including NK cells and quite a few others, which can be manipulated into cancer therapeutics for the treatment of hematologic malignancies.

Some of these are intriguing early preclinical research that may form next generation technologies in the future, while others take the form of up and coming early clinical data that readers may be interested to learn more about.

Here we highlight nine emerging immunotherapy approaches to consider that don’t involve T cells…

Curious to find out more about these novel ideas or iterations and get a heads up on insights from our ASH19 commentary? Subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by